BIOTRONIK Blog Explore our latest insightful interviews and articles Image Blog Stories Filter and Search Filter by year - Any -20252024202320222021 Search 51 blog articles Image October 25, 2024 Blog BIOTRONIK’s Longstanding Cooperation with Die ARCHE: A Partnership for Children Image September 16, 2024 Blog Shaping Health Behaviors in Patients with Coronary Heart Disease Optimizing Patient Experience With eHealth Solutions Image March 7, 2024 Blog Improving Cardiovascular Health This International Women’s Day Image February 14, 2024 Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits Image January 31, 2024 Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024 Image December 22, 2023 Blog Gold Standard for Two Decades: Why the Use of GoldTip is Still Unbeaten in Certain Ablation Procedures In the midst of celebrating 60 years of service in partnership with the healthcare community, BIOTRONIK’s Electrophysiology business marked another important milestone of its own in 2023 – its 20 th anniversary. Image December 12, 2023 Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Continues 2023 was a landmark year for BIOTRONIK – not simply in name or number – but in action. The company’s 60 th year of operations was a busy one for lifesaving innovations like the Amvia pacemaker and CRT-P family and Oscar catheter, to laying the groundwork for helping a whole new community of patients with the Prospera TM spinal cord stimulation system, a BIOTRONIK first. Image December 11, 2023 Blog Vascular Revolution Spurs Overdue Update to Radiation Guidelines Prof. Anders Wanhainen Highlights New ESVS Recommendations, Advising on Suspended Personal Radiation Protection Systems for the First Time Image November 24, 2023 Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Spread Globally What began with one lifesaving mission between two students in early 1960s Berlin now spans the globe: BIOTRONIK is active in more than 100 countries. Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page Next › Subscribe for our News You must have JavaScript enabled to use this form. Title Select TitleMsMrMXDrProf First name Last name Role Please select your roleHealthcare ProfessionalPatient or RelativeJournalistOther Email Phone Country/Region - Select -AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d’IvoireDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorth KoreaNorth MacedoniaNorwayOmanOutlying OceaniaPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSamoaSan MarinoSarkSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaSão Tomé & PríncipeTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkmenistanTurks & Caicos IslandsTuvaluTürkiyeU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Topic Please select a topicProductsPatientsHealthcare Professionals I prefer to be contacted by Phone Email Message *Fields are mandatory. Latest Press Releases Show all press releases Image June 4, 2025 BUELACH, Switzerland Press Release First Patient Enrolled in Leave Nothing Behind-Trial Comparing Drug-Coated Balloon-Based Strategy to Drug-Eluting Stents in Chronic Total Occlusion Patients Today BIOTRONIK announces the enrollment of the first patient in the Leave Nothing Behind-Trial. The first implantation was performed by Dr. Mohamed Ayoub at the Heart and Diabetes Center North Rhine-Westphalia, Germany. The trial aims to demonstrate the non-inferiority of drug-coated balloons (DCB) or DCBs in combination with Resorbable Magnesium Scaffolds (RMS) compared to drug-eluting stents (DES) in chronic total occlusions (CTO) in percutaneous coronary interventions (PCI). The prospective, single-center, single-blind, randomized trial evaluates the efficacy of the Pantera ® Lux ® DCB and Image May 21, 2025 PARIS, France Press Release BIOMAG-I Data Shows No New Events between Two and Three Years in Target Lesion Failure with Freesolve Resorbable Magnesium Scaffold New results from the BIOMAG-I first-in-human trial demonstrated an excellent safety and efficacy profile for Freesolve ®, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS) at three years follow-up. Prof. Dr. Michael Haude presented these new data at the EuroPCR 2025 conference in Paris. At the 36-month follow-up, the target lesion failure (TLF) rate remained at 3.5%, consisting of four cases of clinically driven target lesion revascularization (CD-TLR), of which only one event occurred beyond the resorption period of the scaffold. No cases of target-vessel myocardial infarction Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next Press Contact Corporate Public Relations & Communications press@biotronik.com +49 (0) 30 68905 1414 Get in contact
Image October 25, 2024 Blog BIOTRONIK’s Longstanding Cooperation with Die ARCHE: A Partnership for Children
Image October 25, 2024 Blog BIOTRONIK’s Longstanding Cooperation with Die ARCHE: A Partnership for Children
Image September 16, 2024 Blog Shaping Health Behaviors in Patients with Coronary Heart Disease Optimizing Patient Experience With eHealth Solutions
Image September 16, 2024 Blog Shaping Health Behaviors in Patients with Coronary Heart Disease Optimizing Patient Experience With eHealth Solutions
Image February 14, 2024 Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits
Image February 14, 2024 Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits
Image January 31, 2024 Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024
Image January 31, 2024 Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024
Image December 22, 2023 Blog Gold Standard for Two Decades: Why the Use of GoldTip is Still Unbeaten in Certain Ablation Procedures In the midst of celebrating 60 years of service in partnership with the healthcare community, BIOTRONIK’s Electrophysiology business marked another important milestone of its own in 2023 – its 20 th anniversary.
Image December 22, 2023 Blog Gold Standard for Two Decades: Why the Use of GoldTip is Still Unbeaten in Certain Ablation Procedures In the midst of celebrating 60 years of service in partnership with the healthcare community, BIOTRONIK’s Electrophysiology business marked another important milestone of its own in 2023 – its 20 th anniversary.
Image December 12, 2023 Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Continues 2023 was a landmark year for BIOTRONIK – not simply in name or number – but in action. The company’s 60 th year of operations was a busy one for lifesaving innovations like the Amvia pacemaker and CRT-P family and Oscar catheter, to laying the groundwork for helping a whole new community of patients with the Prospera TM spinal cord stimulation system, a BIOTRONIK first.
Image December 12, 2023 Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Continues 2023 was a landmark year for BIOTRONIK – not simply in name or number – but in action. The company’s 60 th year of operations was a busy one for lifesaving innovations like the Amvia pacemaker and CRT-P family and Oscar catheter, to laying the groundwork for helping a whole new community of patients with the Prospera TM spinal cord stimulation system, a BIOTRONIK first.
Image December 11, 2023 Blog Vascular Revolution Spurs Overdue Update to Radiation Guidelines Prof. Anders Wanhainen Highlights New ESVS Recommendations, Advising on Suspended Personal Radiation Protection Systems for the First Time
Image December 11, 2023 Blog Vascular Revolution Spurs Overdue Update to Radiation Guidelines Prof. Anders Wanhainen Highlights New ESVS Recommendations, Advising on Suspended Personal Radiation Protection Systems for the First Time
Image November 24, 2023 Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Spread Globally What began with one lifesaving mission between two students in early 1960s Berlin now spans the globe: BIOTRONIK is active in more than 100 countries.
Image November 24, 2023 Blog 60 Years of Saving Lives – How the BIOTRONIK Mission Spread Globally What began with one lifesaving mission between two students in early 1960s Berlin now spans the globe: BIOTRONIK is active in more than 100 countries.
Image June 4, 2025 BUELACH, Switzerland Press Release First Patient Enrolled in Leave Nothing Behind-Trial Comparing Drug-Coated Balloon-Based Strategy to Drug-Eluting Stents in Chronic Total Occlusion Patients Today BIOTRONIK announces the enrollment of the first patient in the Leave Nothing Behind-Trial. The first implantation was performed by Dr. Mohamed Ayoub at the Heart and Diabetes Center North Rhine-Westphalia, Germany. The trial aims to demonstrate the non-inferiority of drug-coated balloons (DCB) or DCBs in combination with Resorbable Magnesium Scaffolds (RMS) compared to drug-eluting stents (DES) in chronic total occlusions (CTO) in percutaneous coronary interventions (PCI). The prospective, single-center, single-blind, randomized trial evaluates the efficacy of the Pantera ® Lux ® DCB and
Image June 4, 2025 BUELACH, Switzerland Press Release First Patient Enrolled in Leave Nothing Behind-Trial Comparing Drug-Coated Balloon-Based Strategy to Drug-Eluting Stents in Chronic Total Occlusion Patients Today BIOTRONIK announces the enrollment of the first patient in the Leave Nothing Behind-Trial. The first implantation was performed by Dr. Mohamed Ayoub at the Heart and Diabetes Center North Rhine-Westphalia, Germany. The trial aims to demonstrate the non-inferiority of drug-coated balloons (DCB) or DCBs in combination with Resorbable Magnesium Scaffolds (RMS) compared to drug-eluting stents (DES) in chronic total occlusions (CTO) in percutaneous coronary interventions (PCI). The prospective, single-center, single-blind, randomized trial evaluates the efficacy of the Pantera ® Lux ® DCB and
Image May 21, 2025 PARIS, France Press Release BIOMAG-I Data Shows No New Events between Two and Three Years in Target Lesion Failure with Freesolve Resorbable Magnesium Scaffold New results from the BIOMAG-I first-in-human trial demonstrated an excellent safety and efficacy profile for Freesolve ®, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS) at three years follow-up. Prof. Dr. Michael Haude presented these new data at the EuroPCR 2025 conference in Paris. At the 36-month follow-up, the target lesion failure (TLF) rate remained at 3.5%, consisting of four cases of clinically driven target lesion revascularization (CD-TLR), of which only one event occurred beyond the resorption period of the scaffold. No cases of target-vessel myocardial infarction
Image May 21, 2025 PARIS, France Press Release BIOMAG-I Data Shows No New Events between Two and Three Years in Target Lesion Failure with Freesolve Resorbable Magnesium Scaffold New results from the BIOMAG-I first-in-human trial demonstrated an excellent safety and efficacy profile for Freesolve ®, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS) at three years follow-up. Prof. Dr. Michael Haude presented these new data at the EuroPCR 2025 conference in Paris. At the 36-month follow-up, the target lesion failure (TLF) rate remained at 3.5%, consisting of four cases of clinically driven target lesion revascularization (CD-TLR), of which only one event occurred beyond the resorption period of the scaffold. No cases of target-vessel myocardial infarction
Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next
Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next